BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

502 related articles for article (PubMed ID: 22252451)

  • 1. Action and reaction: the biological response to siRNA and its delivery vehicles.
    Kanasty RL; Whitehead KA; Vegas AJ; Anderson DG
    Mol Ther; 2012 Mar; 20(3):513-24. PubMed ID: 22252451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The design and exogenous delivery of siRNA for post-transcriptional gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Sohail M; Akhtar S
    J Drug Target; 2004 Jul; 12(6):315-40. PubMed ID: 15545082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted delivery of short interfering RNAs--strategies for in vivo delivery.
    Wullner U; Neef I; Tur MK; Barth S
    Recent Pat Anticancer Drug Discov; 2009 Jan; 4(1):1-8. PubMed ID: 19149683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. siRNA therapeutics: a clinical reality.
    Saw PE; Song EW
    Sci China Life Sci; 2020 Apr; 63(4):485-500. PubMed ID: 31054052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicogenomics of non-viral drug delivery systems for RNAi: potential impact on siRNA-mediated gene silencing activity and specificity.
    Akhtar S; Benter I
    Adv Drug Deliv Rev; 2007 Mar; 59(2-3):164-82. PubMed ID: 17481774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic siRNA: principles, challenges, and strategies.
    Gavrilov K; Saltzman WM
    Yale J Biol Med; 2012 Jun; 85(2):187-200. PubMed ID: 22737048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and Biological Evaluation of a Novel Integrin α
    Chen X; Liu M; Wang R; Yan P; Zhang C; Ma C; Yin L
    Molecules; 2017 Feb; 22(2):. PubMed ID: 28165399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid nanoparticles for short interfering RNA delivery.
    Leung AK; Tam YY; Cullis PR
    Adv Genet; 2014; 88():71-110. PubMed ID: 25409604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA: Mechanism of action, challenges, and therapeutic approaches.
    Alshaer W; Zureigat H; Al Karaki A; Al-Kadash A; Gharaibeh L; Hatmal MM; Aljabali AAA; Awidi A
    Eur J Pharmacol; 2021 Aug; 905():174178. PubMed ID: 34044011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery strategies for siRNA-mediated gene silencing.
    Gilmore IR; Fox SP; Hollins AJ; Akhtar S
    Curr Drug Deliv; 2006 Apr; 3(2):147-5. PubMed ID: 16611001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bio-inspired materials in drug delivery: Exploring the role of pulmonary surfactant in siRNA inhalation therapy.
    De Backer L; Cerrada A; Pérez-Gil J; De Smedt SC; Raemdonck K
    J Control Release; 2015 Dec; 220(Pt B):642-50. PubMed ID: 26363301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of RNA interference against cancer.
    Takeshita F; Ochiya T
    Cancer Sci; 2006 Aug; 97(8):689-96. PubMed ID: 16863503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: a promising approach in liver-specific RNAi delivery.
    Sajeesh S; Lee TY; Kim JK; Son DS; Hong SW; Kim S; Yun WS; Kim S; Chang C; Li C; Lee DK
    J Control Release; 2014 Dec; 196():28-36. PubMed ID: 25251899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in siRNA delivery in cancer therapy.
    Singh A; Trivedi P; Jain NK
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review.
    Chaturvedi K; Ganguly K; Kulkarni AR; Kulkarni VH; Nadagouda MN; Rudzinski WE; Aminabhavi TM
    Expert Opin Drug Deliv; 2011 Nov; 8(11):1455-68. PubMed ID: 21867463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving siRNA bio-distribution and minimizing side effects.
    Scaggiante B; Dapas B; Farra R; Grassi M; Pozzato G; Giansante C; Fiotti N; Grassi G
    Curr Drug Metab; 2011 Jan; 12(1):11-23. PubMed ID: 21222588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted delivery of siRNA by nonviral vectors: lessons learned from recent advances.
    Li SD; Huang L
    Curr Opin Investig Drugs; 2008 Dec; 9(12):1317-23. PubMed ID: 19037838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.